Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06422338
Other study ID # EChiLiBRiST CT1
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date December 1, 2024
Est. completion date March 1, 2027

Study information

Verified date May 2024
Source Barcelona Institute for Global Health
Contact Quique Bassat, Prof
Phone 93 227 92 12
Email quique.bassat@isglobal.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The overall aim of the study is to provide evidence that introducing soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) evaluation at triaging (first clinical assessment), in combination with IMCI-based guidelines (SoC), is a viable strategy to enhance rapid and accurate identification of febrile children at increased risk of life-threatening infections compared to IMCI-based strategies alone (SoC), and to demonstrate whether this results in enhanced decisions of admission/referral vs discharge, and enhanced overall health outcome of children with acute fever in sub-Saharan Africa.


Description:

This is a multi-country, open label, two-arm, parallel-group, superiority, individually randomised clinical trial involving 2,606 febrile children per country (two countries, total n=5212). The trial will compare the performance of a point-of-care rapid triage test (POC-RTT) based on sTREM-1 levels (i.e. B-Triage) (in combination with IMCI-based strategies, which are the SoC) to appropriately support admission/referral vs discharge decisions during the first clinical assessment of febrile children aged 2-<60 months compared to the standard of care based on IMCI guidelines. Febrile children meeting the study eligibility criteria will be randomly allocated (1:1) to one of the two triaging approaches (arms): 1) IMCI-based standard of care (SoC); or 2) IMCI-enhanced by sTREM-1 levels (SoC + sTREM-1 POC). Blood will be collected from all participants and only those randomised to the intervention arm (arm 2) will have sTREM-1 levels determined at the POC using B-Triage device. At baseline, all children will undergo two clinical assessments. Primary composite endpoint of "appropriateness of discharge" will be based on the first clinical assessment, which is more representative of real-world clinical practice. However, the ultimate decision on admission/referral vs discharge will be based on the second clinical assessment, which will ensure the safest possible clinical practice in the context of a clinical trial. 1. At baseline, during the first clinical assessment, all participants will be evaluated following the SoC based on IMCI guidelines, which will guide management decisions, including clinical diagnosis and treatment. This IMCI-guideline based evaluation during this first clinical assessment will be conducted by a health worker as per routine clinical practice in the outpatient departments of each study site. 1. In the participants randomised to the control arm, decision of admission/referral vs discharge home will be informed by IMCI-based evaluation alone (SoC). 2. In the participants randomised to the intervention arm, decision of admission/referral vs discharge home will be informed by IMCI-based evaluation enhanced by sTREM-1 levels (SoC + sTREM-1 POC). Clinicians will be instructed to admit for further observation any child with sTREM-1 levels equal or superior to 200 pg/mL, as these patients are at moderate or high risk of adverse outcomes and death. On the other hand, children with sTREM-1 levels below 200 pg/mL will be eligible for discharge home at the criteria of the clinician, considering the signs and symptoms found, and based on IMCI guidelines. Hence, should clinicians in charge deem that any of these children still require admission, they will be instructed to continue with the admission regardless of sTREM-1 levels. The study intervention will be implemented during the first clinical assessment, and consequently, primary composite endpoint of "appropriateness of discharge" will be based on the decision of admission/referral vs discharge home during this first clinical assessment, which is more representative of routine clinical practice in each study site. 2. All randomised participants will be also evaluated by an independent study physician in a second clinical assessment, for the implementation of a systematised clinical evaluation (IMCI-based) to uncover any danger signs or severity criteria potentially missed or misinterpreted during the first assessment. This second assessment will also include clinical variables of the clinical scores Paediatric Early Warning Score (ED-PEWS), Lactate enhanced-quick Sequential Organ Failure Assessment (LqSOFA) and Logistic Organ Dysfunction Score (LODS), as well as temperature and oxygen saturation measures. Hence, study clinicians during this second clinical assessment might be able to uncover more symptoms and signs that are admission criteria due to the tools available in the context of this clinical trial. Initially discharged patients from both arms showing a danger sign or other severity criteria during this second assessment will be admitted, as well as those from the intervention arm with sTREM-1 high-risk (red light) and moderate-risk (yellow light) levels, in case that the first clinician might not have adhered to the protocol during the first assessment. On the other hand, this second assessment will not overturn the decision of the first clinician if admission has been decided in case of sTREM-1 levels below 200 pg/mL (green light, low-risk). This second clinical assessment will guide the ultimate decision on admission/referral vs discharge in order to ensure the safest possible clinical practice in the context of a clinical trial. Moreover, those participants with respiratory symptoms will be eligible for the respiratory tract infection (RTI) sub-study, where digital lung auscultations, a mid-turbinate nasal swab and a saliva sample will be collected. Throughout the study, all participants will receive treatment as per the routine clinical practice and SoC for each diagnosis at each study site, administered by clinical staff routinely working in the participating facilities. All participants will have follow-up evaluations by study clinicians on days 3 and 7 post-enrolment, or at any time in-between in case of clinical deterioration according to caregivers' evaluation. All participants will be also followed-up on day 28 for an interview to follow-up on serious adverse events (SAEs), as well as to collect information on secondary consultations and hospitalisation, or death. A follow-up extra visit at day 91 (month 3) can be conducted for an interview to ask for hospitalisation or death.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 5212
Est. completion date March 1, 2027
Est. primary completion date December 1, 2026
Accepts healthy volunteers No
Gender All
Age group 2 Months to 60 Months
Eligibility Inclusion Criteria: - Age =2 months and <60 months - Written informed consent from the child's parent or caregiver - History of fever for =7 days OR hypothermia (i.e., axillary temperature <35.5ºC) OR suspected severe infection (e.g., in children with moderate or severe acute malnutrition). - Lives within the catchment area of the study facility and must intend to continue to reside there for the duration of the study - For the RTI sub-study only: presence of respiratory symptoms compatible with RTI. Exclusion Criteria: - Weight less than 2.5kg - Main reason for consultation is an injury, trauma or acute poisoning - Enrolled in another clinical trial testing a new drug - Enrolled in a vaccine trial in the last 3 months. - Any other condition determined by the investigators that makes it unlikely that the participant would complete the study

Study Design


Intervention

Other:
IMCI-enhanced by sTREM-1 levels (SoC + sTREM-1 POC)
IMCI-guidelines (standard of care) + Point-Of-Care Rapid Triage Test (POC-RTT) based on sTREM-1 quantification

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Barcelona Institute for Global Health

Outcome

Type Measure Description Time frame Safety issue
Other Secondary consultations or admission Proportion of secondary consultations or admissions on day 91 (month 3) among the two study arms Up to day 91
Other Mortality Proportion of mortality on day 91 (month 3) among the two study arms. Up to day 91
Primary Appropriateness of discharge The primary outcome is the proportion of "appropriateness of discharge" according to the first clinical assessment of febrile children aged 2-<60 months compared among the 2 study arms.
Inappropriate discharge is defined as a composite of (fulfilling at least one of the following):
Presence at baseline of World Health Organization (WHO)-proposed danger signs in discharged children; OR
Presence of WHO-proposed danger signs on day 3 post-discharge; OR
Requirement for additional visit at the health facility or admission at day 7; OR
Death on day 7 post-discharge. The absence of any of these endpoints will be considered an appropriate discharge.
Up to day 7
Secondary Secondary consultations or admissions Proportion of secondary consultations or admissions on day 7 and day 28 among the two study arms. Up to day 28
Secondary Mortality Proportion of mortality on day 7 and day 28 among the two study arms. Up to day 28
Secondary Referrals to higher level facilities Proportion of referrals of mild infections to higher level facilities at day 7 and day 28 among the two study arms. Up to day 28
Secondary Severe disease Proportion of participants diagnosed with severe disease as described in IMCI (i.e. very severe diseases, severe pneumonia, severe dehydration, severe persistent diarrhoea, very severe febrile diseases, severe complicated measles, complicated severe acute malnutrition, mastoiditis, and severe anaemia), at day 3 and day 7 among the two study arms. Up to day 7
Secondary Symptoms duration Median time to symptoms resolution among the two study arms until day 28. Up to day 28
Secondary Hospital stay length Median length of hospital stay among the two study arms until day 28 Up to day 28
Secondary Serious adverse events Proportion of serious adverse events (SAEs) at day 3, day 7, and day 28, among the two study arms. Up to day 28
See also
  Status Clinical Trial Phase
Completed NCT06190457 - Safety and Efficacy of Intrathecal Rituximab in 16 Children of Stage Ⅲ、ⅣNon-Hodgkin Lymphoma
Recruiting NCT04691349 - CAR-T for r/r Malignant Tumors in Children Early Phase 1
Not yet recruiting NCT06455592 - Effect of APA on Sleep Quality in Children With Cancer From 5 to 16 Years N/A
Not yet recruiting NCT05566951 - Technology-Based Psychosocial Empowerment Program for Home Care of Children With Cancer and Their Parents N/A
Not yet recruiting NCT05806983 - Evaluation of the Efficiency of the Technology-Based Psychosocial Empowerment Program Program N/A
Recruiting NCT05329467 - Validation of Pain Assessment Scale Faces Thermometer Scale (FTS) N/A
Not yet recruiting NCT04016506 - Epidemiology, Management and Complications Related to Pancreatic Trauma in Children
Recruiting NCT05761847 - Pediatric Medication Therapy Management Trial N/A
Not yet recruiting NCT06291012 - Stopping Pneumonia Antibiotherapy Regimen Early Phase 4
Not yet recruiting NCT05943587 - The Development and Evaluation of Pain Neuroscience Education in Children N/A
Recruiting NCT05109013 - Juvenile Essential Arterial Hypertension and Vascular Function
Completed NCT04846400 - Pilot Study of a Self-Supporting Nasopharyngeal Airway in Hypotonia N/A
Completed NCT04040036 - Effects of Virtual Reality on Pain, Fear and Anxiety During Blood Draw in Children Aged 5-12 Years Old N/A
Completed NCT03312881 - Neuropathic Pain in Children: Multimodal Assessment and Diagnosis
Completed NCT04334733 - The Impact of Preprocedural Animation About Echocardiography Display and Kaleidoscope Display on Anxiety in Children N/A
Completed NCT06220383 - Evaluation of The Effect of Crowns Applied With Hall Technique on Occlusion N/A
Completed NCT03941392 - Nutritional Study in Spanish Pediatric Population
Completed NCT03244332 - HEMOCC Study. Hemostasis in Cirrhotic Children. N/A
Not yet recruiting NCT06299267 - The Effect of Dual Task on Manual Skill Performance in Children and Adolescents N/A
Active, not recruiting NCT04070131 - Horse Assisted Rehabilitation Postoncologic Treatment in Children and Adolescents: Physical and Psychological Effects N/A